As cutaneous melanoma (CM) currently remains with a bleak prognosis. thorough investigation of new treatment options are of utmost relevance. In the phase II/III randomized clinical trial (CASVAC-0401). the repeated immunization of stages IIB-III CM patients with the irradiated. https://www.rxkaitori.com/product-category/bright-source-emergency-batteries/